Acute Myeloid Leukemia (AML): Symptoms, Subtypes, Diagnosis, and Treatment
Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy characterized by rapid proliferation of immature myeloid precursors (blasts) in the bone marrow, blood, and occasionally extramedullary sites. It is the most common acute leukemia in adults (median age ~68).
Clinical Presentation
Symptoms reflect bone marrow failure and blast infiltration:
- Anemia: Fatigue, weakness, exertional dyspnea, pallor
- Thrombocytopenia: Petechiae, ecchymoses, mucosal bleeding, menorrhagia
- Neutropenia/Functional immune defect: Fever, infections (bacterial, fungal)
- Constitutional: Fever, night sweats, weight loss
- Leukostasis (WBC >100K): Respiratory distress, neurologic changes, priapism — medical emergency
- Organomegaly: Splenomegaly, hepatomegaly, lymphadenopathy (less prominent than in ALL)
WHO Classification (Simplified)
- AML with defining genetic abnormalities: t(8;21), inv(16), t(15;17) [APL], KMT2A rearrangements, etc.
- AML with myelodysplasia-related changes (AML-MRC)
- Therapy-related AML (t-AML)
- AML, not otherwise specified (NOS)
- Myeloid sarcoma (extramedullary)
Molecular profiling (FLT3, NPM1, TP53, ASXL1, etc.) is essential for risk stratification and targeted therapy selection.
Diagnostic Workup
- CBC with differential, peripheral smear
- Bone marrow aspirate/biopsy: Morphology, flow cytometry, cytogenetics (karyotype + FISH), molecular panel
- Coagulation studies (especially for APL)
- Lumbar puncture if CNS symptoms or high-risk features
- Cardiac evaluation (anthracycline readiness)
- Infectious workup (HIV, hepatitis, CMV)
Treatment Paradigm
Fit Patients (Intensive Therapy Eligible)
- Induction: "7+3" (cytarabine + anthracycline) ± midostaurin (FLT3-mutated) ± gemtuzumab ozogamicin (CD33+)
- Consolidation: High-dose cytarabine (HiDAC) ± allogeneic transplant (based on risk, donor, MRD)
- APL (t(15;17)): ATRA + arsenic trioxide ± chemo (non-chemo regimens curative)
Unfit Patients / Older Adults
- Hypomethylating agents (azacitidine, decitabine) + venetoclax: Standard of care; ~65% CR/CRi
- Low-dose cytarabine (LDAC) + venetoclax/glasdegib
- Gilteritinib (FLT3-mutated R/R)
- Clinical trials strongly preferred
Prognosis
- Highly variable by age, cytogenetics, molecular markers, MRD status, fitness
- Younger/favorable risk: 5-yr OS 50–65%
- Older/adverse risk: 5-yr OS <20%
- MRD negativity post-consolidation strongly predicts cure
Urgent referral to an academic/tertiary center with leukemia expertise is critical for optimal outcomes.
Blood Disorders - Related Articles
- Transfusion Reactions: Severity Spectrum, Types, and Outcomes
- Thalassemia Trait: Understanding Diagnosis & Inheritance
- Rheumatoid Factor: Understanding Symptoms and Autoimmune Conditions
- Blood Loss from Cuts: What's Normal & When to Seek Help
- Blood Gas Analysis: What Conditions Can ABG Diagnose?
- Fanconi Anemia: Genetics, Clinical Features, and Multidisciplinary Management
- Arm Deep Vein Thrombosis: Symptoms, Dangers, and Immediate Action Required
